Ruibo Biotechnology-B (06938.HK) and MADRIGAL reach their first milestone in collaboration.

Intelligence Times Finance APP News, ReBobio-B (06938.HK) announced that the company has reached the first candidate drug selection milestone in the siRNA collaboration project with Madrigal. The collaboration aims to advance cutting-edge RNA therapy for liver diseases, focusing primarily on metabolic dysfunction-related non-alcoholic steatohepatitis (NASH). This milestone is the result of efficient cooperation between the two parties, and will be followed by the immediate initiation of new drug clinical trial application (IND) supportive studies to support subsequent clinical research.